Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRANC: Regional Anesthesia and Substance P in Head and Neck Cancer
NCT03081897Suspended
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2016
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of ropivacaine in head and neck cancer (HNC), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Expression of Substance P at 2 years. Started Jul 2016; status: suspended.
02
Drugs
ropivacaine
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03081897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081897.